Kabra Drugs Limited has issued a postal ballot notice dated May 8, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice, dispatched electronically to all shareholders whose e-mail addresses are registered as on the cut-off date of Friday, May 8, 2026, seeks member approval through remote e-voting for two special resolutions relating to a name change and an expansion of the company's business objects.

Proposed Name Change to Aanjaay Industries Limited

The Board of Directors, vide a board resolution dated January 1, 2026, approved a proposal to change the company's name from "Kabra Drugs Limited" to "Aanjaay Industries Limited" to reflect the company's new business directions and brand identity. The Registrar of Companies, Ministry of Corporate Affairs, has already granted approval for the proposed name "Aanjaay Industries Limited." The company has stated that the proposed name change would neither result in a change of objects, legal status, constitution, turnover, operations, or activities of the company, nor would it affect any rights or obligations of the company or its shareholders and other stakeholders.

A certificate from practicing Chartered Accountants M/s P P N And Company (Firm Registration Number: 013623S), Chennai, has been enclosed, certifying compliance with conditions prescribed under Sub-Regulation (1) of Regulation 45 of the SEBI Listing Regulations. The certificate confirms that the company has not changed its name since 1992, satisfying the requirement that at least one year must have elapsed since the last name change.

Expansion of Memorandum of Association Objects

The second special resolution proposes to insert twelve new sub-clauses (sub-clauses 4 to 15) after the existing sub-clause 3 in the Main Objects Clause III(A) of the Memorandum of Association. The Board of Directors approved this alteration at its meeting held on Tuesday, April 21, 2026. The company aims to diversify its business activities and capitalize on opportunities across multiple sectors. The proposed new business objects include:

• Drones and defence: Manufacturing, fabricating, designing, and dealing in drone controllers, drones, drone cameras, and drone jammers; providing drone services for aerial topography, crop monitoring, surveillance, and disaster management; and manufacturing and maintaining equipment for assembly of fixed wing, rotary wing, land and naval platforms.
• Electric vehicles: Designing, developing, and dealing in conventional or hydrogen internal combustion engines, battery electric drive systems, battery charging and swapping, fuel cell electric drive systems, and entire vehicles including public and individual transportation systems.
• Renewable energy: Undertaking integrated renewable energy power projects including solar, wind, and other forms of renewable energy, energy storage including Battery Energy Storage Solutions (BESS), and providing Engineering, Procurement and Construction services.
• Steel industry: Manufacturing, processing, importing, exporting, and dealing in all kinds of steel products including billets, rods, bars, sheets, coils, pipes, and alloys.
• Healthcare and hospitals: Research and development in the healthcare sector; designing and operating hospitals, dispensaries, clinics, and laboratories; manufacturing and maintaining medical equipment; and establishing training institutions for medical and para-medical professionals.
• Hospitality and accommodation: Providing and managing accommodation and hospitality services primarily for patients and their attendants, and operating theatres, health clubs, and recreational centers.
• Dairy products: Manufacturing, processing, storing, and dealing in all types of dairy products including milk and allied products, and establishing and running dairy farms.
• Agro industry: Establishing and running agro farms; cultivating and dealing in all kinds of agro products including food grains, seeds, trees, plants, fruits, and vegetables.
• Artificial intelligence and technology: Research, design, development, manufacturing, and dealing in AI technologies, software solutions, and hardware products including machine learning, data analytics, cloud computing, cybersecurity, IoT equipment, and allied products.

E-Voting Schedule and Process Details

The remote e-voting process will be facilitated through CDSL. The key dates and details are as follows:

M/s. Jay Jain & Associates, Practicing Company Secretaries, Mumbai, was appointed as the Scrutinizer at the Board meeting held on April 21, 2026, to conduct the postal ballot through the remote e-voting process in a fair and transparent manner. The result of the postal ballot shall be declared by the Chairman or any other duly authorized person of the Company on or before Friday, June 12, 2026, and will be communicated to the stock exchanges and uploaded on the company's website at www.kabradrugs.com . The last date of e-voting, i.e., Wednesday, June 10, 2026, shall be the date on which the resolutions would be deemed to have been passed, if approved by the requisite majority.

Kabra Drugs has secured board approval to enter the branded generic pharmaceutical products segment, marking a significant strategic move for the company. The expansion will be executed through a phased approach in collaboration with strategic partners, with South India identified as the primary target market for the initial rollout.

Board-Approved Expansion Into Branded Generics

The company's board has formally approved the foray into branded generic products, outlining a structured and phased entry strategy. By partnering with strategic collaborators, Kabra Drugs aims to establish a presence in this segment in a measured and systematic manner.

South India as the Strategic Starting Point

The board's decision designates South India as the first geography for the branded generics initiative. This phased geographic approach reflects a deliberate strategy to build a foundation in a defined market before potentially broadening the scope of operations.

MD to Lead Immediate Implementation

Managing Director Nanjappan Aravind has been tasked with commencing implementation of the board-approved plan without delay. The directive to begin immediately underscores the company's intent to move swiftly in executing its branded generics strategy.